{"DataElement":{"publicId":"7297579","version":"1","preferredName":"No Prior Systemic Therapy For Malignant Neoplasm Administered CPTAC Indicator","preferredDefinition":"A response to indicate whether no prior systemic (chemotherapy or biological) treatment for any malignancy was administered.","longName":"7297573v1.0:6841630v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7297573","version":"1","preferredName":"No Prior Systemic Therapy For Malignant Neoplasm Administered","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Earlier in time or order._Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._The reason of something._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._The act of having given something (e.g., a medication or test).","longName":"7297570v1.0:7297571v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7297570","version":"1","preferredName":"Negation Prior Systemic Therapy","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:Earlier in time or order.:Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"C25594:C25629:C15698","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A691347B-9D1A-5366-E053-4EBD850A44AC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"ONEDATA","dateModified":"2020-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7297571","version":"1","preferredName":"For Malignant Neoplasm Administered","preferredDefinition":"The reason of something.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:The act of having given something (e.g., a medication or test).","longName":"C64956:C9305:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A691347B-9D2C-5366-E053-4EBD850A44AC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"ONEDATA","dateModified":"2020-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A691347B-9D3D-5366-E053-4EBD850A44AC","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"KNABLEJ","dateModified":"2020-06-12","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6841630","version":"1","preferredName":"CPTAC Yes No Unk Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"6841630v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0FF8F1-5A82-3678-E053-F662850A4C36","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"5682957","version":"1","preferredName":"Yes","longName":"5682957","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4DAE-2A6B-7561-E053-F662850A0EBD","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CA9-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CB3-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"Unknown: Could not be determined or unsure","valueDescription":"Indeterminate or Unknown","ValueMeaning":{"publicId":"6841632","version":"1","preferredName":"Indeterminate or Unknown","longName":"6841632","preferredDefinition":"An indication that something is indeterminate or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate or Unknown","conceptCode":"C157157","definition":"An indication that something is indeterminate or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C86-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A782DA4-CE67-084E-E053-F662850AB283","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6841629","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C157175:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C5B-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C6C-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"GDEEN","dateModified":"2023-11-14","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776734","version":"1","longName":"All Generic CRFs","context":"OCCPR"},{"publicId":"7203746","version":"1","longName":"Screening and Eligibility","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Candidate has not received pr","type":"Preferred Question Text","description":"Candidate has not received prior systemic (chemotherapy or biological) treatment for any malignancy","url":null,"context":"OCCPR"},{"name":"CPTAC-Elig-1","type":"Alternate Question Text","description":"Candidate has not received prior systemic (chemotherapy or biological) treatment for any malignancy (Note: Sarcoma cases may have received treatment > 3 years prior).","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A691D865-C1E2-6181-E053-4EBD850AEABD","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-08-03","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"8/3/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"}}